First Trust Nasdaq Pharmaceuticals ETF
FTXH
30 hedge funds and large institutions have $23.6M invested in First Trust Nasdaq Pharmaceuticals ETF in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 4 closing their positions.
25% more capital invested
Capital invested by funds: $18.9M → $23.6M (+$4.72M)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0.32% more ownership
Funds ownership: 64.76% → 65.08% (+0.32%)
6% less funds holding
Funds holding: 32 → 30 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oppenheimer & Co
New York
|
+$2.56M |
| 2 |
Raymond James Financial
St Petersburg,
Florida
|
+$1.51M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$497K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$383K |
| 5 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$911K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$322K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$277K |
| 4 |
MIM
Marshall Investment Management
Littleton,
Colorado
|
-$249K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$201K |
FTXH Hedge Fund Activity: Q2 2026 in Review
30 of the 8,326 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q2 2026, worth a combined $23.6M — up 25% from $18.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FTXH and 2 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 11 added.
The largest buyer was Oppenheimer & Co, adding an estimated $2.56M. The largest seller was LPL Financial, cutting an estimated $911K.
- 30 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q2 2026, down from 32 in Q1 2026.
- Funds reported $23.6M of First Trust Nasdaq Pharmaceuticals ETF stock for Q2 2026, up 25% quarter-over-quarter.
- 2 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q2 2026 and 4 closed out, a net change of -2 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q2 2026 was Oppenheimer & Co, an estimated $2.56M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q2 2026 was LPL Financial, an estimated $911K sold.
Based on aggregated 13F filings for Q2 2026.